The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
<p>The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>
שמור ב:
| מחבר ראשי: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| מחברים אחרים: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| יצא לאור: |
2025
|
| נושאים: | |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
פריטים דומים
-
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
מאת: Seyed Reza Mousavi (13223324)
יצא לאור: (2025) -
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
מאת: Seyed Reza Mousavi (13223324)
יצא לאור: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
מאת: Seyed Reza Mousavi (13223324)
יצא לאור: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
מאת: Seyed Reza Mousavi (13223324)
יצא לאור: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
מאת: Anna Starshinova (22571846)
יצא לאור: (2025)